340B Orphan Drug Exclusion Seems Untenable, Sen. Hatch Tells HRSA
This article was originally published in The Pink Sheet Daily
Executive Summary
Following the Health Resources and Services Administration’s final rule on excluding orphan drugs from the 340B discount, Sen. Hatch writes to object to the agency’s interpretation of the statutory language.